The text starts here.

Non-Consolidated Semiannual Financial Report for fiscal 1997

SALES BY PRODUCTS

1. ETHICAL DRUGS

(billions of yen)

Product Description FY1996 FY1997
First Half Full Year FFirst Half 97/96
(%percent)
Full Year (Est)
SELBEX Gastritis/gastric ulcer medication 22.9 45.6 22.5 98 44.0
METHYCOBAL Peripheral neuropathies remedy 12.9 25.6 13.6 106 26.0
IOMERON Non-ionic contrast medium 7.2 13.9 7.0 97 13.5
MYONAL Muscle relaxant 5.7 11.1 5.5 97 11.0
GLAKAY Osteoporosis remedy 3.7 8.1 5.5 148 12.0
AZEPTIN Anti-allergy agent 5.0 11.2 4.5 90 10.0
JUVELA
NICOTINATE
Microcirculation activator 4.6 9.2 4.5 99 9.0
NITOROL-R Long-acting isosorbide dinitrate 4.5 9.1 4.3 96 9.0
CELEPORT Cerebral metabolic activator 4.8 9.1 4.1 86 8.0
INHIBACE Long-acting ACE inhibitor 3.7 7.2 3.5 93 6.5
NEUQUINON Metabolic cardiotonic 3.9 7.4 3.4 86 6.5
RULID Long-acting macrolide antibiotic 2.4 5.3 2.2 92 4.5
INFREE Analgesic/anti-inflammatory agent 2.4 4.4 2.0 81 4.0
CORETEC Cardiotonic/acute heart failure 0.2 0.7 0.2 105 1.0
ARICEPT drug substance
(bulk export)
1.7 2.1 2.3 133 4.5
Ethical Drugs Total 105.3 210 104.4 99 210
Reference: Sales in the first half FY1997 of the Alzheimer's disease treatment, ARICEPT, by the Company's subsidiaries were ¥11.0 billion in the US and ¥0.3 billion in Europe. Sales forecasts for FY1997 are ¥24.0 billion in the US and ¥1.5 billion in Europe.

2. OVER-THE-COUNTER DRUGS (billions of yen)

(billions of yen)

Product Group Main Product/ Description FY1996 FY1997
First Half Full Year First Half 97/96
(%percent)
Full Year (Est)
CHOCOLA BB Group CHOCOLA BB/Vitamin B2 preparation 3.4 7.2 3.8 110 7.5
Vitamin-E Group JUVELUX/Natural Vitamin E preparation 2.2 4.8 2.4 111 5.0
SACLON Group SACLON/Indigestion & heartburn remedy 1.9 4.2 1.9 103 4.0
NABOLIN Group Active-type vitamin B12 0.7 1.3 0.8 107 1.5
Bayer Group BAYCLEAR/Athlete's foot remedy 0.5 1.2 0.7 127 1.5
OTC Products Total 11.8 24.6 12.1 102 25.0